Two Years Of Clinical Experience Outcome Review On Radium223 Therapy In Bone Metastatic Castrate-resistent Prostate Cancer

被引：0
|
作者：
Pena, H. [1 ]
Cantinho, G. [1 ]
Graca, A. [1 ]
Fernandes, A. [1 ]
Fernandes, I. [2 ]
Costa, L. [2 ]
机构：
[1] Univ Lisbon, Fac Med, Inst Med Nucl, Lisbon, Portugal
[2] Ctr Hosp Lisboa Norte, S Oncol, Lisbon, Portugal
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2018年 / 45卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
EP-0681
引用
收藏
页码：S571 / S571
页数：1
相关论文
共 50 条
  • [31] Radium Ra 223 Alpha Therapy for Prostate Cancer Bone Metastasis
    Strane, Timothy
    RADIOLOGIC TECHNOLOGY, 2021, 92 (06) : 618 - 622
  • [32] Outcome of Radium-223 in metastatic castrate resistant prostate cancer: an audit to assess real life experience at the Northern Centre for Cancer Care, Newcastle-upon-Tyne.
    Leaning, D. J.
    Jiang, X.
    Frew, J.
    Sarah, A.
    Driver, I.
    Pedley, I.
    McMenemin, R.
    Azzabi, A.
    CLINICAL ONCOLOGY, 2015, 27 : S5 - S5
  • [33] Clinical experience of hormone therapy to bone metastatic prostate cancer
    Wakisaka, Masami
    Nomura, Kazushi
    INTERNATIONAL JOURNAL OF UROLOGY, 2006, 13 (05) : 550 - 554
  • [34] Imaging response during therapy (tx) with radium-223 (Ra-223) for castrate resistant prostate cancer (CRPC) with bone metastases (BM)
    Keizman, Daniel
    Peer, Avivit
    Neumann, Avivit
    Rosenbaum, Eli
    Neiman, Victoria
    Gottfried, Maya
    Kuchuk, Iryna
    Sarid, David
    Gez, Eliahu
    Mermershtain, Wilmosh
    Rouvinov, Keren
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [35] Clinical Correlates of Benefit From Radium-223 Therapy in Metastatic Castration Resistant Prostate Cancer
    Alva, Ajjai
    Nordquist, Luke
    Daignault, Stephanie
    George, Saby
    Ramos, Jorge
    Albany, Costantine
    Isharwal, Sudhir
    McDonald, Matthew
    Campbell, Gregory
    Danchaivijitr, Pongwut
    Yentz, Sarah
    Anand, Aseem
    Yu, Evan Y.
    PROSTATE, 2017, 77 (05): : 479 - 488
  • [36] Outcomes with Radium-223 therapy in clinical practice of metastatic castration resistant prostate cancer (mCRPC).
    Alva, Ajjai Shivaram
    Nordquist, Luke T.
    Daignault, Stephanie
    George, Saby
    Ramos, Jorge
    Isharwal, Sudhir
    McDonald, Matthew
    Campbell, Gregory
    Danchaivijitr, Pongwut
    Albany, Costantine
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [37] Four years of clinical experience with Radium-223 for the treatment of castration-resistant prostate cancer
    Alvarez Perez, R. M.
    Delgado Garcia, A.
    Garcia Martinez, S.
    Sanz Viedma, S.
    Palacios Gerona, H.
    Pajares Vinardel, M.
    Jimenez-Hoyuela Garcia, J. M.
    REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2019, 38 (05): : 298 - 304
  • [38] Review of Radium-223 and Metastatic Castration-Sensitive Prostate Cancer
    Dandapani, Savita V.
    Wong, Jeffrey
    Twardowski, Przemyslaw
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2020, 35 (07) : 490 - 496
  • [39] Radium-223 therapy in symptomatic metastatic castrate resistant prostate cancer (mCRPC) - sequential use post-abiraterone/prednisolone
    Jiang, Xue Yan
    Atkinson, Sarah
    Cumming, Sam
    Burns, Alexander
    Pearson, Rachel
    Frew, John
    McMenemin, Rhona
    Azzabi, Ashraf
    Leaning, Darren
    Pedley, Ian
    CLINICAL ONCOLOGY, 2019, 31 : E10 - E11
  • [40] Use of radium-223 in heavily pretreated metastatic castrate resistant prostate cancer (mCRPC) patients.
    Modi, Dipenkumar
    Kim, SeongHo
    Mamdani, Hirva Mansurali
    Hwang, Clara
    Gayar, Hersham
    Vaishampayan, Ulka N.
    Joyrich, Richard
    Heath, Elisabeth I.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
12345